Dalpiciclib

Clinical trials of HDAC inhibitors in BRCA are widespread, with Chidamide, Vorinostat, and Entinostat being the most studied. Most trials are in early phases, combining HDAC inhibitors with other treatments like hormone therapy, targeted therapy, and immunotherapy, reflecting the complexity of BRCA's molecular subtypes. Further research is needed to understand the mechanisms of HDAC inhibitor treatments in BRCA.

Article references discuss various aspects of breast cancer management, including global statistics, neoadjuvant chemotherapy, imaging biomarkers, AI applications, and predictive models for treatment response.